Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom

Korinna Jöhrens, Josephine Fischer, Markus Möbs, Klaus Junker, Jutta Kirfel, Sven Perner, Silke Laßmann, Martin Werner, Vanessa Borgmann, Hendrik Bläker, Michael Hummel2021 · DOI

TL;DR

This paper presents the results of a proficiency testing (ring trial) for detecting the BRAF V600E mutation in metastatic colorectal cancer (mCRC). The study found that molecular methods for detecting BRAF V600E mutations are significantly more reliable and accurate than immunohistochemistry (IHC), highlighting the importance of molecular testing for guiding targeted therapies in mCRC.

What Problem Does This Paper Address?

Precision oncology relies heavily on accurate molecular diagnostics to guide treatment decisions. In metastatic colorectal cancer (mCRC), the detection of KRAS and NRAS mutations has been standard for determining eligibility for EGFR-blocking antibodies. Recently, the BRAF V600E mutation has emerged as another crucial predictive marker. Patients with mCRC harboring this mutation can benefit from a specific treatment regimen involving encorafenib (a BRAF inhibitor) and cetuximab (an anti-EGFR antibody), a therapy approved in 2020. This approval necessitates reliable and accurate detection of the BRAF V600E mutation in pathology labs. The paper addresses the challenge of ensuring this diagnostic accuracy by evaluating the performance of both molecular and immunohistochemical methods through a ring trial.

Methods

The study employed a ring trial, a quality assurance measure where multiple laboratories analyze the same set of samples. The QulP GmbH organized this trial, which involved two main approaches for detecting the BRAF V600E mutation:

  • Immunohistochemistry (IHC): Using an antibody specifically targeting the V600E-mutated BRAF protein.
  • Molecular Methods: Employing various DNA-based techniques.

The trial involved an internal ring trial first to select suitable cases, followed by an open ring trial where participating laboratories received 10 mCRC cases. They were tasked with analyzing these cases using either IHC or molecular methods within a set timeframe. Performance was evaluated based on accuracy, with points awarded for correct identification of positive and negative cases.

Datasets

The study utilized 10 cases of colorectal carcinoma with and without BRAF V600E mutations, sourced from the archives of the lead institute (Charité Berlin). These cases were prepared as tissue blocks and sectioned for distribution to participating laboratories. The age of these blocks varied from 10 to 133 months.

Key Insights and Ideas

  • Molecular Superiority: The most striking insight is the clear superiority of molecular methods over immunohistochemistry for detecting BRAF V600E mutations in mCRC. This has direct implications for patient care, as inaccurate IHC results could lead to the exclusion of patients who would benefit from targeted therapy.
  • Therapeutic Significance: The BRAF V600E mutation is a critical biomarker for selecting patients who can benefit from specific, chemotherapy-free treatment options, underscoring the need for highly accurate diagnostic tests.
  • Methodological Diversity: The molecular testing landscape is diverse, with participants using a wide range of techniques, including Next-Generation Sequencing (NGS), pyrosequencing, qPCR, and Sanger sequencing, as well as various commercial kits and laboratory-developed tests (LDTs). Despite this heterogeneity, molecular methods demonstrated high success rates.
  • IHC Challenges: Immunohistochemistry, while conceptually simpler, presented significant challenges. Issues with staining intensity and interpretation led to a lower success rate among participants using IHC, suggesting potential difficulties in standardization and reproducibility across different labs.

Key Results

  • Molecular Testing: Out of 42 participants using molecular methods, all achieved successful participation (100% success rate). Of the 420 individual analyses performed, 418 (99.5%) were correct, with only one false positive and one technically unassessable result. The sensitivity for molecular analysis was 100.0% and specificity was 99.2%.
  • Immunohistochemistry: Of the 9 participants using IHC, only 6 (67%) achieved successful participation. A significant portion of individual analyses (11.1%) were technically unassessable, and 7.8% were incorrect. The sensitivity for IHC was 90.6% and specificity was 92.6%.
  • Method Usage: A large majority of participants (42 out of 51) opted for molecular testing, while only 9 chose IHC.

Limitations and Future Work

  • IHC Limitations: The paper highlights that IHC, while potentially useful, is not recommended as a standalone method for therapy decisions due to its lower reliability compared to molecular methods. The observed issues with weak staining intensity in IHC could be influenced by factors like tissue fixation and the use of older, larger resection specimens in ring trials versus smaller biopsies in routine diagnostics. The authors suggest parallel analysis of routine samples with ring trial samples to ensure consistent staining protocols.
  • Future Work: The study strongly advocates for molecular methods as the preferred approach for BRAF V600E mutation detection in pathology labs to ensure accurate patient selection for targeted therapies. Further standardization and validation of IHC protocols might be necessary if it is to be considered a viable alternative or complementary method.

Summary updated

Abstract

Zusammenfassung Ringversuche sind ein wichtiges Instrument zur Qualitätssicherung. Dies betrifft in zunehmendem Maße auch die molekulare Diagnostik in der Pathologie, von deren Ergebnissen Therapieentscheidungen in der Präzisionsonkologie direkt abhängen. Beim metastasierten kolorektalen Karzinom (mKRK) stand bisher der Nachweis von KRAS -und NRAS -Mutationen im Vordergrund, deren Abwesenheit eine Therapie mit EGFR-blockierenden Antikörpern ermöglicht. Nun ist BRAF als weiterer prädiktiver Marker hinzugekommen, da mKRK Patienten mit einer BRAF -V600E-Mutation nach systemischer Vortherapie von einer Behandlung mit Encorafenib (einem BRAF-Inhibitor) in Kombination mit Cetuximab (Anti-EGFR-Antikörper) profitieren. Aufgrund der 2020 erfolgten Zulassung für diese Behandlung ist es wichtig, dass der diagnostische Nachweis einer BRAF -V600E-Mutation zuverlässig in den Pathologien durchgeführt werden kann. Daher wurde dieser Ringversuch durchgeführt, bei dem der Nachweis der BRAF -V600E-Mutation entweder mittels Immunhistochemie oder molekularer Verfahren erfolgen konnte. Die Ergebnisse des Ringversuchs belegen eindeutig, dass derzeit die molekulare BRAF -V600E-Bestimmung dem immunhistologischen Nachweis überlegen ist.
BibTeX
@inproceedings{johrens2021nachweis,
  author = {Korinna Jöhrens and Josephine Fischer and Markus Möbs and Klaus Junker and Jutta Kirfel and Sven Perner and Silke Laßmann and Martin Werner and Vanessa Borgmann and Hendrik Bläker and Michael Hummel},
  title = {{Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom}},
  booktitle = {Der},
  year = {2021},
  doi = {10.1007/s00292-021-01022-8},
}
Figure